Literature DB >> 12958597

Mutations in NHLRC1 cause progressive myoclonus epilepsy.

Elayne M Chan1, Edwin J Young, Leonarda Ianzano, Iulia Munteanu, Xiaochu Zhao, Constantine C Christopoulos, Giuliano Avanzini, Maurizio Elia, Cameron A Ackerley, Nebojsa J Jovic, Saeed Bohlega, Eva Andermann, Guy A Rouleau, Antonio V Delgado-Escueta, Berge A Minassian, Stephen W Scherer.   

Abstract

Lafora progressive myoclonus epilepsy is characterized by pathognomonic endoplasmic reticulum (ER)-associated polyglucosan accumulations. We previously discovered that mutations in EPM2A cause Lafora disease. Here, we identify a second gene associated with this disease, NHLRC1 (also called EPM2B), which encodes malin, a putative E3 ubiquitin ligase with a RING finger domain and six NHL motifs. Laforin and malin colocalize to the ER, suggesting they operate in a related pathway protecting against polyglucosan accumulation and epilepsy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958597     DOI: 10.1038/ng1238

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  117 in total

1.  Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.

Authors:  Erica Tiberia; Julie Turnbull; Tony Wang; Alessandra Ruggieri; Xiao-Chu Zhao; Nela Pencea; Johan Israelian; Yin Wang; Cameron A Ackerley; Peixiang Wang; Yan Liu; Berge A Minassian
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.

Authors:  Anna A DePaoli-Roach; Vincent S Tagliabracci; Dyann M Segvich; Catalina M Meyer; Jose M Irimia; Peter J Roach
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

3.  The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters.

Authors:  Pankaj Kumar Singh; Sweta Singh; Subramaniam Ganesh
Journal:  Mol Cell Biol       Date:  2011-11-28       Impact factor: 4.272

Review 4.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 5.  Glycogen phosphorylation and Lafora disease.

Authors:  Peter J Roach
Journal:  Mol Aspects Med       Date:  2015-08-13

6.  Glycogen metabolism in tissues from a mouse model of Lafora disease.

Authors:  Wei Wang; Hannes Lohi; Alexander V Skurat; Anna A DePaoli-Roach; Berge A Minassian; Peter J Roach
Journal:  Arch Biochem Biophys       Date:  2006-11-03       Impact factor: 4.013

7.  Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.

Authors:  Shweta Singh; Toshimitsu Suzuki; Akira Uchiyama; Satoko Kumada; Nobuko Moriyama; Shinichi Hirose; Yukitoshi Takahashi; Hideo Sugie; Koichi Mizoguchi; Yushi Inoue; Kazue Kimura; Yukio Sawaishi; Kazuhiro Yamakawa; Subramaniam Ganesh
Journal:  J Hum Genet       Date:  2005-07-15       Impact factor: 3.172

Review 8.  The genetic and molecular bases of monogenic disorders affecting proteolytic systems.

Authors:  I Richard
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

Review 9.  Advances in lafora progressive myoclonus epilepsy.

Authors:  Antonio V Delgado-Escueta
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

10.  Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.

Authors:  Vincent S Tagliabracci; Jean Marie Girard; Dyann Segvich; Catalina Meyer; Julie Turnbull; Xiaochu Zhao; Berge A Minassian; Anna A Depaoli-Roach; Peter J Roach
Journal:  J Biol Chem       Date:  2008-10-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.